SCHEMBL376526

SCHEMBL376526

CC[C@@H]1C(=O)N(C)c2cnc(Nc3ccc(C(=O)Nc4ccc(C=CC[C@H](NC(=O)OC(C)(C)C)C(=O)OC5CCCC5)cc4)cc3OC)nc2N1C1CCCC1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PLK1 P53350 16/20 0.59
PLK3 Q9H4B4 13/20 0.59
PLK2 Q9NYY3 11/20 0.59
PRKD3 O94806 3/20 0.59
CLK2 P49760 3/20 0.59
PTK2 Q05397 3/20 0.59
CAMK2G Q13555 3/20 0.59
CAMK2D Q13557 3/20 0.59
PRKD2 Q9BZL6 3/20 0.59
CSNK1G1 Q9HCP0 3/20 0.59
CSNK1G3 Q9Y6M4 3/20 0.59
MAP4K4 O95819 2/20 0.59
PRKCG P05129 2/20 0.59
RPS6KA3 P51812 2/20 0.59
NEK4 P51957 2/20 0.59
SRPK1 Q96SB4 1/20 0.59
BRD4 O60885 8/20 0.57
TAF1 P21675 4/20 0.57
ALK Q9UM73 4/20 0.57
BRDT Q58F21 2/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL376090 1.00 PLK1 (0.59) PLK1PLK3PLK2PRKD3CLK2
SCHEMBL3780485 0.94 PLK1 (0.62) PLK1PLK3PLK2PRKD3CLK2
SCHEMBL3780471 0.94 PLK1 (0.62) PLK1PLK3PLK2PRKD3CLK2
SCHEMBL13227837 0.92 PLK1 (0.64) PLK1PLK3PLK2PRKD3CLK2
SCHEMBL376180 0.89 PLK1 (0.65) PLK1PLK3PLK2PRKD3CLK2
SCHEMBL376241 0.89 PLK1 (0.53) PLK1PLK3PLK2PRKD3CLK2
SCHEMBL376243 0.89 PLK1 (0.53) PLK1PLK3PLK2PRKD3CLK2
SCHEMBL13260666 0.89 PLK1 (0.59) PLK1PLK3PLK2PRKD3CLK2
SCHEMBL376099 0.89 PLK1 (0.59) PLK1PLK3PLK2PRKD3CLK2
SCHEMBL13260931 0.86 PLK1 (0.67) PLK1PLK3PLK2PRKD3CLK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2079743-B1 PTERIDINE DERIVATIVES AS POLO-LIKE KINASE INHIBITORS USEFUL IN THE TREATMENT OF CANCER CHROMA THERAPEUTICS LTD (GB) 2012-01-25 EP disclosed